PTC Therapeutics, Inc. (PTCT) Q2 FY26 Earnings Call

Safiance momentum drove higher guidance, supported by international expansion and strong prescription renewal metrics [2][21].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Call date2026-07-30
Length62 minutes
EPS$0.92
Revenue$360.5M

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

All PTCT earnings ยท Back to PTCT overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.